Novogyne Pharmaceuticals’ CombiPatch (estrogen/progestin) transdermal hormone replacement therapy (HRT) may improve libido in older women who experience a lack of sex drive because of declining hormone levels, according to a preliminary study presented Tuesday.
CombiPatch, the only FDA-approved combination estrogen/progestin HRT patch to treat symptoms of menopause, is marketed in the US by Novogyne, a joint venture between Noven and Novartis. Dr. Subir Roy of the University of Southern California presented the study results at the 10th World Congress on Menopause in Berlin, according to a Tuesday statement issued by Noven.
Noven spokesman Joe Jones told Reuters Health that Dr. Roy’s study was partly funded by Rhone-Poulenc Rorer (now Aventis), the prior licensee of CombiPatch. Novogyne acquired the rights to CombiPatch in March 2001.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!